AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$REGN

Pitofsky Jason sold $170K of REGN (indirect holdings)

Pitofsky Jason (SVP Controller) sold 179 indirectly-held shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $950.76 ($0.17M total) on 2026-11-04.

Original reporting
SEC EDGAR · Pitofsky Jason
Published Nov 6, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$REGN
Bearish
medium confidence
Mentioned
$REGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNBearishLow
01

Why it matters

The transaction is a primary disclosure but of modest size, offering limited trading insight.

02

Market read

A small insider sale that may cause slight short-term price pressure but lacks broader market significance.

03

What to watch

No disclosed reason for sale; could be tax planning or personal liquidity needs.

Relevance 4/10Novelty 3/10Timing: same day filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$REGNBearishMedium confidence
Context

SVP Controller Pitofsky Jason sold 179 shares for $170,186, leaving a zero holding.

Expected impact

likely modest pressure as the market prices in the insider divestiture

Evidence & confidence

Small insider sell of $170k is material enough to be noted but unlikely to move the stock significantly.

Market effects

Sector

Minimal impact on biotech sector; typical insider sell.

Regional

No broader regional effect.

Global

Limited to REGN investors.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a signal of trouble.

Key entities

  • Individual
    Pitofsky Jason

    SVP Controller at Regeneron Pharmaceuticals

  • Company
    Regeneron Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker REGN

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REGN insider trading history →

Related articles

$LLYHighAI 8/10

Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher

Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.

etfdb.com
HighAI 8/10

Why is Regeneron Pharmaceuticals stock surging today?

Regeneron Pharmaceuticals' stock rose 4.0% to a 52-week high of $972.06 after reporting Q3 2026 earnings of $20.07 per share, up 70% Y/Y, and revenue of $5.116B, up 36% Y/Y. Multiple analysts raised price targets, with BofA Securities at $1,030 and Canaccord Genuity at $1,175. Positive Phase 3 trial data for Libtayo also supported the stock.

investing.com
$REGNMedAI 9/10

Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter

Regeneron (REGN) shares rose 13.33% to a 52-week high after reporting Q3 earnings and revenue above expectations, driven by its partnership with Sanofi on Dupixent. Adjusted earnings were $20.07 per share, up 70% YoY, and revenue rose 36% to $5.12 billion. Collaboration revenue from Sanofi reached $2.7 billion, up 68% YoY. The company also expanded its alliance with Sanofi, with a $1 billion upfront payment expected in Q4.

ibtimes.com.au